{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:49Z","timestamp":1793394529637,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,9,3]],"date-time":"2011-09-03T00:00:00Z","timestamp":1315008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10120-011-0091-8","type":"journal-article","created":{"date-parts":[[2011,9,6]],"date-time":"2011-09-06T17:33:29Z","timestamp":1315330409000},"page":"154-161","source":"Crossref","is-referenced-by-count":145,"title":["Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination"],"prefix":"10.1007","volume":"15","author":[{"given":"Shigenobu","family":"Emoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroharu","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kaisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,3]]},"reference":[{"key":"91_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"91_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","volume":"21","author":"H Ishigami","year":"2010","unstructured":"Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67\u201370.","journal-title":"Ann Oncol"},{"key":"91_CR3","first-page":"960","volume":"54","author":"Y Kodera","year":"2007","unstructured":"Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, et al. Intraperitoneal paclitaxel: a possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology. 2007;54:960\u20133.","journal-title":"Hepatogastroenterology"},{"key":"91_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/PL00011715","volume":"3","author":"M Kochi","year":"2000","unstructured":"Kochi M, Fujii M, Kanamori N, Kaiga T, Kawakami T, Aizaki K, et al. Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer. Gastric Cancer. 2000;3:177\u201386.","journal-title":"Gastric Cancer"},{"key":"91_CR5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","volume":"6","author":"Y Takahashi","year":"2003","unstructured":"Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142\u20135.","journal-title":"Gastric Cancer"},{"key":"91_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jjco\/29.11.550","volume":"29","author":"T Yamao","year":"1999","unstructured":"Yamao T, Kai S, Kazami A, Koizumi K, Handa T, Takemoto N, et al. Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer. Jpn J Clin Oncol. 1999;29:550\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"91_CR7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"91_CR8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419\u201323.","journal-title":"Int J Gynecol Cancer"},{"key":"91_CR9","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/(SICI)1097-0142(19981215)83:12<2488::AID-CNCR12>3.0.CO;2-1","volume":"83","author":"B Nakata","year":"1998","unstructured":"Nakata B, Hirakawa-YS Chung K, Kato Y, Yamashita Y, Maeda K, Onoda N, et al. Serum CA125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998;83:2488\u201392.","journal-title":"Cancer"},{"key":"91_CR10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4143\/crt.2004.36.3.178","volume":"36","author":"GI Hwang","year":"2004","unstructured":"Hwang GI, Yoo CH, Sohn BH, Shin JH, Park YL, Kim HD, et al. Predictive value of preoperative serum CEA, CA19-9 and CA125 levels for peritoneal metastasis in patients with gastric carcinoma. Cancer Res Treat. 2004;36:178\u201381.","journal-title":"Cancer Res Treat"},{"key":"91_CR11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1055\/s-2002-33228","volume":"34","author":"T Fujimura","year":"2002","unstructured":"Fujimura T, Kinami S, Ninomiya I, Kitagawa H, Fushida S, Nishimura G, et al. Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer. Endoscopy. 2002;34:569\u201374.","journal-title":"Endoscopy"},{"key":"91_CR12","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/bjs.1800770918","volume":"77","author":"DJ Byrne","year":"1990","unstructured":"Byrne DJ, Browning MC, Cuschieri A. CA72-4: a new tumour marker for gastric cancer. Br J Surg. 1990;77:1010\u20133.","journal-title":"Br J Surg"},{"key":"91_CR13","first-page":"1272","volume":"54","author":"V Goral","year":"2007","unstructured":"Goral V, Yesilbagdan H, Kaplan A, Sit D. Evaluation of CA72-4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology. 2007;54:1272\u20135.","journal-title":"Hepatogastroenterology"},{"key":"91_CR14","first-page":"866","volume":"44","author":"M Ikeguchi","year":"1997","unstructured":"Ikeguchi M, Katano K, Saitou H, Tsujitani S, Maeta M, Kaibara N. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma. Hepatogastroenterology. 1997;44:866\u201371.","journal-title":"Hepatogastroenterology"},{"key":"91_CR15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejso.2011.01.019","volume":"37","author":"S Sougioultzis","year":"2011","unstructured":"Sougioultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis. Eur J Surg Oncol. 2011;37:312\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"91_CR16","unstructured":"Japanese Research Society for Gastric Cancer. The general rules for gastric cancer study (in Japanese). 12th ed. Tokyo: Kanehara Co. & Ltd.; 1993."},{"key":"91_CR17","unstructured":"Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma (in English). 1st ed. Tokyo: Kanehara Co. & Ltd.; 1995."},{"key":"91_CR18","first-page":"1645","volume":"24","author":"P Bystr\u00f6m","year":"2010","unstructured":"Bystr\u00f6m P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, et al. An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer. Oncol Rep. 2010;24:1645\u201352.","journal-title":"Oncol Rep"},{"key":"91_CR19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10120-006-0360-0","volume":"9","author":"J Whiting","year":"2006","unstructured":"Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer: a review. Gastric Cancer. 2006;9:74\u201381.","journal-title":"Gastric Cancer"},{"key":"91_CR20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2010.08.028","volume":"119","author":"DW Cramer","year":"2010","unstructured":"Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, et al. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol. 2010;119:462\u20138.","journal-title":"Gynecol Oncol"},{"key":"91_CR21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","volume":"1","author":"N Scholler","year":"2007","unstructured":"Scholler N, Urban N. CA125 in ovarian cancer. Biomark Med. 2007;1:513\u201323.","journal-title":"Biomark Med"},{"key":"91_CR22","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1038\/onc.2010.87","volume":"29","author":"S Bafna","year":"2010","unstructured":"Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893\u2013904.","journal-title":"Oncogene"},{"key":"91_CR23","first-page":"896","volume":"46","author":"S Adachi","year":"1994","unstructured":"Adachi S, Noda T, Kiyozuka Y, Ito K, Itani Y, Tsujimoto A, et al. The importance of CA125 immunohistochemical staining in patients with ovarian cancer (in Japanese). Acta Obstet Gynaecol Jpn. 1994;46:896\u2013902.","journal-title":"Acta Obstet Gynaecol Jpn"},{"key":"91_CR24","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1158\/1078-0432.CCR-04-2236","volume":"11","author":"JL Dennis","year":"2005","unstructured":"Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766\u201372.","journal-title":"Clin Cancer Res"},{"key":"91_CR25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000290955","volume":"78","author":"J Kitayama","year":"2010","unstructured":"Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology. 2010;78:40\u20136.","journal-title":"Oncology"},{"key":"91_CR26","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","volume":"279","author":"A Rump","year":"2004","unstructured":"Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190\u20138.","journal-title":"J Biol Chem"},{"key":"91_CR27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","volume":"5","author":"JA Gubbels","year":"2006","unstructured":"Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50.","journal-title":"Mol Cancer"},{"key":"91_CR28","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.78.5.3199","volume":"78","author":"D Colcher","year":"1981","unstructured":"Colcher D, Hand PH, Nuti M, Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA. 1981;78:3199\u2013203.","journal-title":"Proc Natl Acad Sci USA"},{"key":"91_CR29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1155\/1998\/738321","volume":"14","author":"ST Fayed","year":"1998","unstructured":"Fayed ST, Ahmad SM, Kassim SK, Khalifa A. The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers. 1998;14:155\u201360.","journal-title":"Dis Markers"},{"key":"91_CR30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1006\/gyno.1993.1026","volume":"48","author":"Y Negishi","year":"1993","unstructured":"Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, et al. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol. 1993;48:148\u201354.","journal-title":"Gynecol Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0091-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-011-0091-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-011-0091-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T10:19:06Z","timestamp":1559125146000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-011-0091-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["91"],"URL":"https:\/\/doi.org\/10.1007\/s10120-011-0091-8","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,3]]}}}